Offer document published for unconditional mandatory cash offer for Allergy Therapeutics by ZQ Capital with a valuation of £48 million
October 2023
Established in 2016, ZQ Capital is one of the fastest growing investment firms in Asia. With unique investment strategies, the firm has a strong track record of delivering consistent returns to investors.
They specialize in identifying deep value opportunities with relentless focus on investment discipline, risk management and preservation of principal. Leveraging their deep network and know-how in China, they form strong collaborative partnerships with their portfolio companies to empower transformational growth and value creation.
ZQ Capital has offices in Hong Kong, Shanghai and Singapore and is a regulated entity under Hong Kong SFC with license type 1, 4, 6 and 9.
Allergy Therapeutics is an AIM listed international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost the performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.
Following the completion by Allergy of an equity financing round announced back in April, ZQ vehicle Skygem Acquisition now has 2.85 billion Allergy shares, a 59.96% stake. Exceeding a 30% stake, ZQ is required to make a mandatory cash offer for the entire company.
Publication of the Offer Document
The Perivan shareholder communications team was delighted to work with Cavendish Securities who acted as financial adviser and Goodwin who acted as legal adviser to SkyGem Acquisition on the production of the Offer Document and Form of Acceptance, which were successfully published and posted to qualifying shareholders on 19th October 2023.
For more information, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
